Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PMDA Announces Measures to Improve Its Services
October 24, 2005
- Control Medical Spending Based on Growth in "Aging-adjusted GDP": Council Experts
October 24, 2005
- UTOBRAIN SEMINAR
October 24, 2005
- Korosho to Include MOF's Viewpoints in Its Healthcare Reform Plan Proposal for FY2006
October 24, 2005
- Pfizer Establishes Website on Research Tools in Collaboration with US NIH
October 24, 2005
- Aripiprazole Recommended for Approval
October 24, 2005
- Are Placebo-controlled Studies Essential for Antidepressants?: Dr Sato of TRC
October 24, 2005
- REGULATORY NEWS IN BRIEF
October 24, 2005
- JHSF Seminars on Drug Discovery Research
October 24, 2005
- Drug Distribution Council Resumes Discussions
October 24, 2005
- JAPIC Seminar on Optimal Healthcare for Patients
October 24, 2005
- Eisai, TorreyPines Announce New Research Program for Alzheimer's Disease
October 24, 2005
- R&D NEWS IN BRIEF
October 24, 2005
- Nippon Kayaku to Make Full Entry into Generic Anticancer Drugs
October 24, 2005
- Correct Knowledge of MS Is Essential: Nihon Schering
October 24, 2005
- BUSINESS NEWS IN BRIEF
October 24, 2005
- DDW-Japan 2005 Held in Kobe
October 24, 2005
- Dr Derek Gilroy Wins Bayer HC's 10th Int'l Aspirin Award
October 24, 2005
- SEMINAR
October 24, 2005
- PMDA to Establish Approval Standards for More OTC Drugs
October 24, 2005
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…